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Summary Loss of heterozygosity (LOH) on chromosome arm 16q occurs in 48-65% of breast tumours. One small region of overlap is
located at 16q24.3. Two genes located in this region, the cellular adhesion regulatory molecule (CMAR) and the breast basic conserved gene
(BBC1), are plausible candidate tumour-suppressor genes. Mutational analysis of the retained copy of these genes has been performed by
direct sequencing in a selected set of breast tumours that show LOH at 16q24.3 but not at other regions on chromosome arm 16q. In CMAR
no other alterations than the previously described 4-bp insertion of CACA at nucleotide 241 could be detected, which was also present in
constitutional DNA of the same patients. This polymorphism occurs homozygously in germline DNA of normal individuals and breast cancer
patients. LOH analysis at this locus shows no preferential loss of a particular variant of the 241 polymorphism. In the BBC1 gene, three
different alterations were found, but only one resulted in an amino acid substitution. This is a known polymorphism, however, also appearing
in germline DNA. The absence oftumour-specific mutations in CMARand BBC1 in this selected series of breast tumours implies that another
gene at 16q24.3 must be the tumour-suppressor gene that is the target for LOH in breast cancer.
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Loss ofheterozygosity (LOH) on the long arm of chromosome 16
occurs frequently in breast cancer and other tumours. Percentages
ofLOH in breast cancer vary from 48% to 65% in different regions
of 16q in different studies (Cleton-Jansen et al, 1994; Tsuda et al,
1994; Dorion-Bonnet et al, 1995). This suggests the presence of
tumour-suppressor genes on this chromosome arm. One of two
identified small regions of overlap is located at 16q24.3 between
the markers APRT and D16S303 (Cleton-Jansen et al, 1994).
Two genes, the cellular adhesion regulatory molecule (CMAR)
and the breast basic conserved gene (BBCJ), located in this region
are probable candidates for the gene targeted by LOH (Adams et
al, 1992; Pullman and Bodmer, 1992; Cleton-Jansen et al, 1995a).
The CMAR gene product enhances binding ofintegrins to extra-
cellular matrix components (Pullman and Bodmer, 1992). A 4-bp
insertion ofCACA at nucleotide 241 occurs in 38% ofCaucasians
and in 30% ofJapanese (Koyama et al, 1992; Durbin et al, 1994).
This 4-bp insertion probably results in an alternative start site for
the gene (Durbin et al, 1994).
The BBC] gene was identified by differential screening of
cDNA libraries of a primary breast carcinoma and of a benign
fibroadenoma (Adams et al, 1992). Expression of this gene is
higher in fibroadenomas than in carcinomas. The gene is
expressed in a great variety of tissues and it is also highly
conserved in other species (Bertauche et al, 1994). At the genetic
level 85% homology is found with the gene coding for the rat ribo-
somal protein L13, at the protein level 97% homology is found
(Olvera et al, 1994).
Received 23January 1997
Revised29 May 1997
Accepted 3 June 1997
Correspondence to: E Moerland, Department of Pathology, Leiden University
Medical Center, Building 1, L1-Q, PO Box 9600, NL-2300 RC Leiden,
The Netherlands
To investigate whether CMAR or BBC] is the tumour-
suppressor gene on 16q24.3 targeted by LOH, we performed
mutational analysis of the retained copy of these genes in breast
tumours that show LOH at 16q24.3.
Moreover, we have addressed the question whether the polymor-
phisms in CMAR and BBC] can occurhomozygously and ifany of
the variants ofthe polymorphisms is specifically deleted by LOH.
MATERIALS AND METHODS
Tumour specimen and control DNA
For this analysis DNA and RNA were isolated from a set of 16
breast tumours ofthe infiltrating ductal type, varying from stage I
to stage IV and with age of onset between 28 and 82 years. All
tumours were removed from patients attending the Leiden
University Hospital. Thirteen cases showed LOH only at 16q24.3
and not at other regions of chromosome arm 16q. Three cases
showed a complex LOH, i.e. loss at 16q24.3 and 16q22.1, and
retention in between. One tumour had LOH at the whole 16q arm
(Figure 1). This set was selected from a series of 230 sporadic
breast tumours on which LOH analysis had been performed
with 37 polymorphic markers on chromosome arm 16q (partly
described in Cleton-Jansen et al, 1994).
For estimating the allele frequencies of the polymorphisms
described here, control DNA isolated from healthy unrelated indi-
viduals from the Leiden region was used.
Detection of the 241 A InsCAcA CMAR polymorphism
To detect the polymorphism polymerase chain reaction (PCR)
reactions were carried out in 12g1 of reaction volumes of a
mixture containing: 100 ng DNA; 0.2 mm dNTPs (optional 1 mC
[32P]dCTP); 6 pmol oligonucleotides; 0.06 U Super Taq; and 1 x
Super Taq buffer (HT Biotechnology, Cambridge, UK). Reactions
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were performed in a thermocycler (MJ Research) under the
following conditions: 1 min at 95°C; 1 min at 55°C; and 1.5 min
at 72°C for 32 cycles. PCR products were separated on a 6%
denaturing acrylamide gel and visualized by autoradiography.
Primers used for amplification were:
CMAR For 2: 5'-TCCAAACAGACCCCTGTTC-3'
CMAR Rev 3: 5'-AGCTCCTCTGCATTAGAGCTG-3'
The reverse primer CMAR Rev 3, located at the 3' UTR, was
designed to screen the complete coding sequence from CMAR.
This was performed by sequencing the CMAR cosmid NL-87D4.
This cosmid was obtained by screening achromosome 16-specific
library with CMAR cDNA probe, kindly provided by Sir Walter
Bodmer.
Subsequently, a digestion with BglI fornon-radioactive detection
was performed. The 241 A InsCACA destroys aBgll restriction site.
Mutation analysis of CMAR
Non-32P-labelled CMAR PCR fragments were screened for muta-
tions after Easy Prep system purification (Pharmacia) by cycle
sequencing (1 min at95°C; 1 min at 55°C; and 1.5 min at720C for
32 cycles) with a cycle-sequencing kit (Amplicycle sequencing
kit, Perkin Elmer) with nested primers:
CMAR For 1: 5'-ATGCCGATGCTTGCAC-3'
CMAR For 3: 5'-TAGTCACGCATGCAGTGTTGG-3'
CMAR Rev 2: 5'-GTATCTCAACAATTCTCAGAGCAG-3'
Screening of the BBC1 gene
RNA was isolated from frozen breast tumourtissueusing TRIZOL
reagent (Gibco BRL). Reverse transcription was performed on
2 ig of total RNA, using an Oligo(dT) primer and 5 U of AMV
reverse transcriptase (Boehringer Mannheim), in 20-,ul reactions
containing the recommended buffer, 5 U of RNAsin (Promega)
and 1 mM dNTPs.
PCRreactions were performed on 1 p1 ofcDNA (1 min at 95°C;
1 min at 59°C; and 1.5 min at 720C for 32 cycles).
Primers used for amplification ofthe BBC] coding sequence:
BBC For: 5'-TlTCCGCTCGGCTGTTTT-3'
BBC Rev: 5'-CGACTGATTCCAAGTCCCC-3'
Cycle sequencing (1 min at 95°C; 1 min at 60°C; and 1.5 min at
72°C for 32 cycles) was performed using the following primers:
BBC For nest: 5'-GCAGGAGCCGCAGGGCCGTAG-3'
BBC Rev nest: 5'-GTCCCCAGGAGGGCTTrATT-3'
BBC 10-9 (For): 5'-GGTACCACACGAAGGTGCGC-3'
(kindly provided by S Adams).
Detection of the BBC1 polymorphism on genomic DNA
A first non-radioactive PCR was performed on 100 ng of DNA in
a 50-,ul volume (1 min at 95°C; 1 min at 55°C; and 1.5 min at
72°C for 12 cycles).
BBC 10-10 (For): 5'-CTCTGTTGGCCTCAGTCGCG-3'
BBC 620 (Rev): 5'-ACTCCTTCAGCCGCTG-3' (both
primers provided by S Adams).
A second, seminested PCR was carried out at the same
conditions, for 20 cycles with 1-gl input from the first PCR and
incorporation of32P, in a reaction volume of50,l.
Table 1 Frequency of the CMAR241 A polymorphism in a normal control
population and in breast cancer patients
CMARalleles Control population Breast cancer patients
Homozygous 241 A 83 (72%) 119 (69%)
Homozygous 241 A InsCACA 2 (1.8%) 4 (2.3%)
Heterozygous 29 (25%) 49 (28%)
BBC EX2 (For): 5'-GCAGGAGCCGCAGGGCCGTAG-3'
BBC 620 (Rev): 5'-GCAGGAGCCGCAGGGCCGTAG-3'
As the polymorphism creates a HaeIII restriction site, a HaeIII
digestion was performed resulting in a 24 bp shorter band on 6%
denaturing polyacrylamide gel.
RESULTS AND DISCUSSION
Occurrence of the 241 A InsCAcA polymorphism in
CMAR
The polymorphism results in a4 bp larger PCR fragment, which is
detected on a denaturing polyacrylamide gel. Allele frequencies
on 228 chromosomes ofunrelated Caucasions were 85% for allele
241 A (lowerband) and 15% forthe 241 A InsCAcApolymorphism.
Observed homo- and heterozygosity rates were similar to the
expected rates, i.e. 72% homozygous allele 241 A, 1.8% homozy-
gous polymorphism InsCACA and 26% heterozygous (Table 1). The
occurrence ofthis polymorphism is similartopreviously described
frequencies of 30% (Koyama et al, 1992) and 38% (Durbin et al,
1994). However, homozygosity of 241 A InsCACA has not been
observed previously, probably because of low sample numbers.
Figure 2A shows examples ofhomozygous allele 241 A, homozy-
gous 241 A InsCACA andheterozygous CMAR alleles as detectedby
PCR and autoradiography.
The detection of two normal individuals that are homozygous
for the CMAR 241 A InsCACA allele shows that absence of one of
the variants of the CMAR polymorphism is not deleterious. This
eitherimplicates that the 241 A InsCACA allele encodes a functional
protein or that CMAR is not an indispensable gene.
LOH at CMAR in breast tumours
Constitutional DNA of 172 breast cancer patients was used to
determine the allele frequency of the CMAR 241 A InsCACA poly-
morphism. On 344 chromosomes, the frequency was 83% for
allele 241 A and 17% for the 241 A InsCACA allele. Observed
homo- and heterozygosity rates are similar to the frequencies
observed in the normal control population as shown in Table 1.
A series of 168 breast tumours was tested forLOH atthe CMAR
locus using the 241 A InsCACA polymorphism. Of the 38 informa-
tive cases 25 (66%) showed LOH. This high LOH rate is in
concordance with previous results with other markers from this
chromosomal region (Cleton-Jansen et al, 1994). If CMAR is
involved in tumour suppression, and ifone ofthe variants encodes
a less active protein, one would expect preferential loss of one of
the alleles. However, ofthese cases 13 showed LOH ofthe 241 A
allele and 12 showed LOH of the 241 A InsCACA, indicating no
preferential loss ofallele 241 A.
Figure 2B shows examples of LOH of the 241 A (T3, T4) and
the 241 A InsCACA (Ti) CMAR alleles.
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Figure 1 LOH results at 16q24.3 (LOH results on 23 markers proximal from 16q24.3 are summarized) and mutation analysis of BBC1 and CMARof 16
breast tumours. White, retention; black, loss of heterozygosity; grey, not informative; X, not tested or not interpretable; #, no sequence deviations from the
GenBank sequence (GenBank accession no. CMAR D14075; BBC1: S54769), CACA, insertion on nucleotide 241 A of CMAR, 144 G, 192 T, 385 G,
polymorphisms in BBC1
Mutation analysis of CMAR in breast tumours
Somatic mutation analysis for CMAR in breast cancer has been
reported previously by Koyama et al (1992), who did not detect
mutations. However, Koyama et al did not screen the complete
coding sequence, 21 nucleotides are missing because one of the
primers used is located in the coding sequence. As not all breast
tumours show LOH at 16q and as this chromosome arm is
suspected to contain at least two different tumour-suppressor
genes, we have repeated this analysis on a more specific set of
breast cancer cases, i.e. tumours with LOH only at 16q24.3, not on
other regions of chromosome arm 16q (Figure 1). Figure 1 shows
the LOH results obtained with markers on 16q24.3 and more prox-
imal markers, which were described in Cleton-Jansen et al (1994).
The CMAR gene does not have introns and the complete
sequence was amplified in one PCR reaction on genomic DNA
from the tumours, using primers according to the submitted
sequence (GenBank accession no. S54769) and the sequence from
3'UTR that was determined by sequencing a CMAR-positive
cosmid, NL-87D4. Subsequent sequencing ofthese PCR products
revealed no sequence deviations other than the already known
polymorphism (Figure 1).
Mutation analysis of BBC1 in breast tumours and
polymorphisms in the BBC1 gene
From 13 breast tumours presented in Figure 1, RNA was available
for analysis of the BBC] gene. RT-PCR fragments consisting of
Table 2 Polymorphisms in the BBC1 gene in 13 breast tumours
Base Polymorphism Amino acid Sequence Deviation
position change according to from GenBank
GenBank sequence
144 T-G Nochange 11 (85%) 2 (15%)
192 C-*T Nochange 11 (85%) 2 (15%)
385 A - G Thr - Ala 2 (15%) 11 (85%)
the complete coding sequence of BBC] were generated from this
tumour cDNA and sequenced.
Three different deviations from the GenBank sequence were
found in this gene (Figure 1), two of which did not result in an
amino acid change, 144 T -> G and 192 C -* T. One alteration,
385 A -* G resulted in an amino acid substitution, but this is a
known polymorphism (J Varley, personal communication) that
appears also in germline DNA from the same patient. Table 1
shows the frequency ofthe polymorphisms found in this study.
Polymorphism 385 G, the only alteration that results in an
amino acidchange, occurs in 11 tumours whereas the 385 A allele,
concordant with the GenBank sequence, is seen in only two cases.
To determine whether this is apreferential loss ofthe 385 A allele,
we examined constitutional DNA extracted from peripheral
lymphocytes from the same patients. A two-step PCR was
designed: the first PCR with a forward primer in intron 1 and the
reverse primer in exon 2 to avoid amplification of pseudo genes
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Figure 2 (A) Autoradiogram showing the different alleles of the CMAR
polymorphism: homozygous 241 A allele (lower band, lanes 3, 5 and 8);
homozygous 241 A InsCACA (upper band, lane 4); and heterozygous CMAR
alleles (lanes 1, 2, 6 and 7). (B) LOH results offour tumours heterozygous for
the CMARpolymorphism. Constitutional DNA is represented by N and
tumour DNA is represented by T: tumour 1 shows LOH of the 241 A InsCACA
allele; tumour 2 shows retention; and tumours 3 and 4 show loss of the
241 A allele
(Adams et al, 1992). As this PCR fragment contains numerous
HaeIII sites a second nested PCR was performed, followed by a
HaeIII digestion.
From 11 tested DNAs, seven are homozygous for the 385 G
allele. Two outoffourheterozygous cases showedLOH ofthe 385
A allele and two cases showed LOH of the polymorphic 385 G
allele. Apparently, there is no preferential loss ofthe 385 A allele.
Furthermore, we estimated the allele frequencies of polymor-
phism 385 in 30 healthy, unrelated individuals. In this series, one
homozygous variant 385 A, 21 homozygous variant G and eight
heterozygous individuals were found. In a total of 60 alleles this
results in 10 (17%) variant A and 50 (83%) variant G alleles. This
is in agreement with the allele frequency found in 13 breast cancer
patients (Table 2).
To assess thatLOH has occurred attheBBCJ locus, allele inten-
sities of normal and tumour DNA were determined by phospho-
imager analysis. Imbalance factors (IF) were calculated as
described previously (Cleton-Jansen et al, 1995b). Because ofthe
presence of heteroduplexes formed between wild-type and poly-
morphic strands that cannot be digested by HaeHI, these IFs are
not representative ofthe LOH in these tumours.
Alterations other than the polymorphisms that are described
here (Figure 1) could not be detected.
In conclusion, wehave analysed two genes BBCI and CMARon
16q24.3 that have been frequently suggested previously as candi-
date tumour-suppressor genes, in a selected population of breast
tumours, showing only LOH at 16q24.3, not elsewhere on 16q.
Neither mutations nor preferential loss of particular alleles have
been detected. Therefore, it can be concluded that neither CMAR
nor BBC1 but another gene at 16q24.3 is the target tumour-
suppressor gene for LOH in breast cancer.
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